A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma

NCT06650514 | Recruiting Phase 2

• 2 other identifiers: VHIO230032024-510987-22-00
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open-label, unicentric, single-arm Phase 2 pilot study to serve as a proof-of-concept of OMO-103 safety and activity in patients with advanced high-grade osteosarcoma. Patients will be treated at the RP2D (6.5 mg/kg as a weekly IV infusion) of OMO-103 to estimate anti-tumour activity and further characterise the safety, tolerability, PK, and PD of OMO-103 in advanced high-grade osteosarcoma patients. Ten (10) evaluable patients will be enrolled. At least 30% of patients will be \<18 years old. The first three patients 12-15 years of age will undergo additional safety monitoring. Patients will be treated until progression by RECIST v1.1 or intolerable toxicity.

Conditions

Osteosarcoma; Osteosarcoma in Children

Outcome Measures

Primary Outcomes (1)

• Preliminary anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma

  Progression-free survival rate at 16 weeks (16-week PFS)

  16 weeks from start of treatment

Secondary Outcomes (14)

• Further evaluate the anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma.

  Until disease progression, unacceptable toxicity, patient request, physician's decision to withdraw treatment, subsequent anticancer therapy, or death whichever occurs first, assessed up to 24 months

• Further evaluate the anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma.

  Until disease progression, unacceptable toxicity, patient request, physician's decision to withdraw treatment, subsequent anticancer therapy, or death whichever occurs first, assessed up to 24 months

• Further evaluate the anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma.

  Until disease progression, unacceptable toxicity, patient request, physician's decision to withdraw treatment, subsequent anticancer therapy, or death whichever occurs first, assessed up to 24 months

• Further evaluate the anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma.

  Until disease progression, unacceptable toxicity, patient request, physician's decision to withdraw treatment, subsequent anticancer therapy, or death whichever occurs first, assessed up to 24 months

• Further evaluate the anti-tumour activity of OMO-103 monotherapy in patients with high-grade osteosarcoma.

  Until disease progression, unacceptable toxicity, patient request, physician's decision to withdraw treatment, subsequent anticancer therapy, or death whichever occurs first, assessed up to 24 months

Study Arms (1)

OMO-103

EXPERIMENTAL

OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles)

Drug: OMO-103

Interventions

OMO-103 DRUG

OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles).

OMO-103

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Provision of signed and dated informed consent form.
• Age ≥12 years at time of informed consent.
• Histologically proven, advanced high-grade osteosarcoma not suitable for local treatments with curative intent
• Confirmed disease progression by radiological report to at least one line of standard chemotherapy containing cisplatin and anthracycline, and no more than 2 previous lines.
• Measurable disease as per RECIST v1.1 criteria and documented by CT/MRI (Appendix 1 - RECIST Response Criteria). NOTE: Lesions to be used as measurable disease for the purpose of response assessment must either:
• not reside in a field that has been subjected to prior radiotherapy, or
• have demonstrated clear evidence of radiographic progression since the completion of prior radiotherapy and prior to study enrolment.
• Provision of a newly obtained tumour biopsy (either from the primary tumour or from metastases) during screening and on-treatment from all patients \>16 years of age. Notes:
• The identified lesion to be biopsied should not have been previously irradiated and should not be the only lesion being used as a measurable-disease target lesion for objective response assessment. Patients must have tumour lesions that can be accessible for biopsy with acceptable clinical risk in the judgement of the Investigator.
• In case a patient has had a tumour biopsy in the previous 6 months and a paraffin block is available, a new biopsy does not need to be done at Screening (if they have received no treatment after biopsy).
• Documented progression on or following the last line of therapy.
• ECOG performance status 0-2 (Appendix 2 - Performance Status Criteria).
• Life expectancy of ≥ 12 weeks as estimated by the treating physician.
• Resolution of all acute, reversible toxic effects of prior therapy or surgical procedure to Grade ≤1 (except alopecia and peripheral neuropathy to Grade ≤2).
• Adequate organ function.

You may not qualify if:

• Treatment with systemic anti-cancer therapy within three weeks prior to study drug administration for chemotherapy and 5 half-lives for targeted therapies.
• Radiation therapy within four weeks prior to study entry. Localised palliative radiotherapy to nontarget lesions is allowed
• Low-grade osteosarcoma, parosteal, or periosteal osteosarcoma.
• Prior history of other malignancies other than osteosarcoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of the disease for at least 2 years.
• Non-malignant systemic disease including cerebrovascular accident, unstable angina pectoris, unstable atrial fibrillation, unstable cardiac arrhythmia, myocardial infarction in the last six months, New York Heart Association (NYHA) Class III or IV heart failure (Appendix 5 - New York Heart Association Criteria).
• Patients with active uncontrolled infection or known to be serologically positive for human immunodeficiency virus (HIV), hepatitis B (except after vaccination) or hepatitis C infection. Investigators may test as per their discretion.
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
• Patients with symptomatic or unstable central nervous system primary tumour or metastases and/or sarcomatous meningitis
• Live vaccine in the last four weeks.
• Current participation in another interventional therapeutic trial.
• Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study.
• Knowledge of any other disease or medication that may interfere with study treatment.
• Patients with known allergies or hypersensitivity reactions to the active substance or to any of its excipients

Sponsors & Collaborators

• Oregon Health and Science University: collaborator
• Vall d'Hebron Institute of Oncology: lead
• Peptomyc S.L.: collaborator
• Osteosarcoma Institute: collaborator
• Curing Kids' Cancer Foundation: collaborator
• Dana-Farber Cancer Institute: collaborator
• Memorial Sloan Kettering Cancer Center: collaborator
• The Morgan Adams Foundation: collaborator
• The Kristen Ann Carr Fund: collaborator

Study Sites (1)

Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain

RECRUITING

MeSH Terms

Conditions

Osteosarcoma

Condition Hierarchy (Ancestors)

Neoplasms, Bone Tissue; Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Sarcoma

Central Study Contacts

Claudia M Valverde

CONTACT

+34932746085; cvalverde@vhio.net

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 14, 2024
• First Posted: October 21, 2024
• Study Start: December 27, 2024
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: January 10, 2025

Record last verified: 2024-11

Locations

ES (1)